4D Molecular Therapeutics : Goldman Sachs 2025 presentation (6591c3)
FDMT
Published on 06/11/2025 at 13:13
Goldman Sachs 2025 Healthcare Conference
Corporate Presentation June 2025
© 2025 4D Molecular Therapeutics. All Rights Reserved.
© 2025 4D Molecular Therapeutics. All Rights Reserved.
4D-150 Key Updates
4D-150
Over 50 clinical trial sites activated to date
RMAT: Regenerative Medicine Advanced Therapy designation
Multi-Billion Dollar
Annual Opportunity
$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept
4D-150
Addresses Primary
Clinical Unmet Need
Topline Data from wet AMD Pivotal Trials in 2027
Readouts from both Phase 3 studies in 4FRONT global registration program expected in H2 2027
Ease of Clinical & Commercial Adoption
Favorable Safety Profile
Single IVT injection: Seamless integration into retina clinic practice flow and buy & bill reimbursement model
Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus (remains standard-of-care, >64M eyes treated)
Backbone therapy with multi-year durability: Foundational therapy with paradigm-shifting treatment burden reduction & vision preservation
Multi-Billion Dollar
Annual Opportunity
$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept
4D-150
Addresses Primary
Clinical Unmet Need
Topline Data from wet AMD Pivotal Trials in 2027
Readouts from both Phase 3 studies in 4FRONT global registration program expected in H2 2027
Ease of Clinical & Commercial Adoption
Favorable Safety Profile
Single IVT injection: Seamless integration into retina clinic practice flow and buy & bill reimbursement model
Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus (remains standard-of-care, >64M eyes treated)
Backbone therapy with multi-year durability: Foundational therapy with paradigm-shifting treatment burden reduction & vision preservation
Disclaimer
4D Molecular Therapeutics Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 11, 2025 at 17:12 UTC.